AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
The 2018 annual meeting of stockholders for Aytu BioScience, Inc. for the fiscal year ended June 30, 2018 was held on June 27, 2018. Of the 35,883,069 shares outstanding on the record date for the meeting, a total of 27,180,123 shares were present or represented at the meeting.
At the meeting, our stockholders elected five members to our board of directors as follows:
|Members||Number of Votes Cast For||Number of Votes Cast Against||Number of Votes Withheld||Number of Broker Non-Votes|
|Joshua R. Disbrow||10,015,887||1,562,549||15,601,687|
|Gary V. Cantrell||9,931,570||1,646,866||15,601,687|
|Carl C. Dockery||9,937,116||1,641,320||15,601,687|
|John A. Donofrio, Jr.||10,238,033||1,340,403||15,601,687|
|Michael E. Macaluso||9,967,263||1,611,173||15,601,687|
The election of directors was determined by a plurality of the votes cast at the meeting, whereby the five nominees receiving the highest number of “FOR” votes were elected as directors.
At the meeting, our stockholders took the following actions:
Did not approve an amendment to our certificate of incorporation to increase the number of authorized shares of common stock from 100,000,000 to 300,000,000 shares of common stock. The vote was 16,288,316 shares for, 10,321,933 shares against, 569,874 shares abstaining, and no shares of broker non-votes;
Approved, by a majority of the shares of our outstanding capital stock, an amendment to our certificate of incorporation to effect a reverse stock split at a ratio of any whole number up to 1-for-20, as determined by the board of directors, at any time before our next annual meeting. The vote for such approval was 18,053,733 shares for, 8,948,996 shares against, 177,394 shares abstaining, and no shares of broker non-votes; and
Ratified, by a majority of the shares voting at the meeting, the appointment of EKS&H, LLLP as our independent registered public accounting firm for the fiscal year ending June 30, 2018. The vote for such approval was 22,207,381 shares for, 2,657,778 shares against, 2,314,964 shares abstaining, and no shares of broker non-votes.
About AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.